Abundant osteoclasts in the subchondral bone of the juvenile Thoroughbred metacarpus suggest an important role in joint maturation.
Authors: Gilday Rebecca, Richard Hélène, Beauchamp Guy, Fogarty Ursula, Laverty Sheila
Journal: Equine veterinary journal
Summary
# Editorial Summary Bisphosphonate therapy in young racehorses remains contentious among practitioners, primarily because these drugs inhibit osteoclast-mediated bone remodelling and may persist within the mineralised bone matrix, potentially compromising skeletal development and the horse's capacity to repair exercise-induced microdamage. Gilday and colleagues investigated the distribution and abundance of osteoclasts within the subchondral bone of juvenile Thoroughbred metacarpi, reasoning that understanding normal osteoclast activity during growth would establish a baseline against which to evaluate bisphosphonate safety. Their histological analysis revealed substantially higher osteoclast numbers in the subchondral regions of skeletally immature animals compared with mature counterparts, indicating that these bone-resorbing cells play a critical physiological role in endochondral ossification, cartilage-bone interface remodelling and skeletal maturation rather than merely responding to pathological demand. For practitioners—particularly those advising on performance management and medication protocols for young stock—these findings suggest that bisphosphonate administration during the formative years may indeed interfere with essential developmental processes, warranting careful consideration of timing, duration and clinical necessity before deployment in juvenile athletes. The work underscores the need for evidence-based guidance on bisphosphonate use during skeletal maturation and highlights osteoclast biology as a key consideration when weighing the benefits of anti-resorptive therapy against potential developmental costs.
Read the full abstract on PubMed
Practical Takeaways
- •Caution is warranted when using bisphosphonates in young racehorses, as these drugs may disrupt the active bone remodelling necessary for proper joint maturation and articular surface development
- •Understanding the critical role of osteoclasts in juvenile joint maturation should inform evidence-based decisions about bisphosphonate administration protocols in juvenile and growing athletes
- •The knowledge that bisphosphonates remain bound to mineralised bone matrix highlights the potential for long-term interference with joint adaptation and bone healing in young horses undertaking athletic training
Key Findings
- •Abundant osteoclasts are present in subchondral bone of juvenile Thoroughbred metacarpus, indicating active bone remodelling during joint maturation
- •Osteoclasts participate in endochondral ossification and subchondral bone remodelling processes critical to joint surface development
- •Bisphosphonate use in juvenile racehorses may interfere with normal osteoclastic bone remodelling and subsequent bone adaptation to exercise